Cue Biopharma (CUE)
(Real Time Quote from BATS)
$1.43 USD
+0.07 (4.76%)
Updated Apr 29, 2024 01:10 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Income Statements
Fiscal Year end for Cue Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 5 | 1 | 15 | 3 | 3 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 5 | 1 | 15 | 3 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 58 | 54 | 59 | 48 | 40 |
Income After Depreciation & Amortization | -52 | -53 | -44 | -45 | -37 |
Non-Operating Income | 3 | 1 | 0 | 0 | 0 |
Interest Expense | 1 | 1 | 0 | 0 | 0 |
Pretax Income | -51 | -53 | -44 | -45 | -36 |
Income Taxes | 0 | 0 | 1 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -51 | -53 | -44 | -45 | -37 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -51 | -53 | -44 | -45 | -37 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -52 | -53 | -42 | -44 | -36 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -52 | -53 | -44 | -45 | -37 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 45.76 | 35.65 | 31.29 | 28.69 | 22.04 |
Diluted EPS Before Non-Recurring Items | -1.11 | -1.49 | -1.41 | -1.56 | -1.66 |
Diluted Net EPS (GAAP) | -1.11 | -1.49 | -1.41 | -1.56 | -1.66 |
Fiscal Year end for Cue Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1.82 | 2.10 | 1.38 | 0.19 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 1.82 | 2.10 | 1.38 | 0.19 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 15.50 | 13.52 | 14.90 | 13.57 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -13.68 | -11.42 | -13.52 | -13.38 |
Non-Operating Income | NA | 0.76 | 0.70 | 0.56 | 0.64 |
Interest Expense | NA | 0.36 | 0.29 | 0.23 | 0.37 |
Pretax Income | NA | -13.43 | -11.01 | -13.19 | -13.11 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -13.43 | -11.01 | -13.19 | -13.11 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -13.43 | -11.01 | -13.19 | -13.11 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 47.18 | 46.36 | 44.80 | 44.65 |
Diluted EPS Before Non-Recurring Items | NA | -0.28 | -0.24 | -0.29 | -0.29 |
Diluted Net EPS (GAAP) | NA | -0.29 | -0.24 | -0.29 | -0.29 |